Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This pilot feasibility study evaluates the use of a hyaluronic acid-based spacing gel (Barrigel) in participants with cervical cancer undergoing chemoradiotherapy (chemoRT), including brachytherapy, as part of standard care. The primary goal is to assess feasibility. Other goals include determining whether gel placement can reduce radiation dose to nearby healthy organs (organs at risk, OAR) and improve delivery of the prescribed radiation dose to the tumor. In cervical cancer, the radiation dose to the tumor is often limited by the risk of exposing nearby sensitive organs, such as the rectum, bladder, and other pelvic structures. Vaginal packing techniques and specialized devices are used to protect these organs and ensure effective treatment. Gel spacers are inserted before radiation therapy to create space between the rectum and the cervix, reducing radiation exposure to healthy tissue. Already widely used in prostate cancer treatment in the U.S., gel spacers may also help improve tumor control and reduce treatment-related toxicity in cervical cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wyrażona pisemna zgoda na udział w badaniu.
- •Osoba wyraża chęć i jest w stanie stosować się do zasad badania.
- •Wiek 18 lat lub więcej.
- •Potwierdzony histologicznie lub cytologicznie rak szyjki macicy, planowany do leczenia chemioradioterapią z brachyterapią.
✗ Disqualifies
- •Aktywna infekcja wymagająca leczenia ogólnoustrojowego.
- •Ciąża lub karmienie piersią.
- •Znana alergia na produkty zawierające kwas hialuronowy.
- •Stwierdzona choroba zapalna jelit, np. choroba Leśniowskiego-Crohna lub wrzodziejące zapalenie jelita grubego.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 1, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill
Chapel Hill, United States
Trial contact
Melissa Knutsen
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/2/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.